We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Screening Tool Simplifies Serological Diagnosis of Neurocysticercosis

By LabMedica International staff writers
Posted on 24 Jul 2014
The availability of a rapid serological diagnosis that targets stage-specific antibodies for human cysticercosis is considered very helpful in control programs for estimating the sero-prevalence or burden of the disease in susceptible population groups.

Cysticercosis is a tissue infection caused by hatched oncospheres, a larval form of the pork tapeworm Taenia solium which parasitize the intestinal wall and circulate through the bloodstream, invade the nervous system and form cysts in the brain, leading to neurocysticercosis. More...


Medical parasitologists at the Leiden University Medical Center (The Netherlands) and their American colleagues developed a field-friendly screening tool to simplify serological diagnosis of neurocysticercosis. A total of 63 banked serum samples from patients with confirmed neurocysticercosis were used to validate the assay, and a total of 170 serum samples collected in regions where transmission of cysticercosis does not occur, were used to assess specificity. These samples consisted of a panel of 78 serum samples assembled from healthy residents of the USA and a panel of 92 serum samples from blood bank donors in the Netherlands.

The assay utilizes novel nano-sized up-converting phosphor (UCP) reporter particles in combination with a portable lightweight analyzer and detects antibodies in serum samples reactive with bacterial-expressed recombinant (r) T24H, a marker for detecting neurocysticercosis cases. Three sequential flow steps allow enrichment of antibodies on the Test (T) line and consecutive binding of protein-A coated UCP reporter particles. Antibody binding was determined by measuring 550-nm emission after excitation of the UCP label with a 980 nm infrared (IR) diode. Lateral flow (LF) strips were scanned using a multistrip scanner, modified Packard Fluorocount microplate reader (PerkinElmer; Waltham, MA, USA) and a customized ESEQuant lateral flow reader (LFR) (QIAGEN Lake Constance; Stockach, Germany).

The clinical sensitivity and specificity of the assay to detect cases of human neurocysticercosis with two or more viable brain cysts were 96% and 98%, respectively, using a sample set comprised of sera from 63 confirmed cases and 170 healthy parasite-naïve non-endemic controls. The evaluation of the new test with a set of clinical samples indicated excellent clinical parameters comparable to an enzyme-linked immunosorbent assay (ELISA). Application of new nano-sized UCP reporter label and a lightweight strip analyzer, both from easily accessible sources, demonstrated equivalent performance compared to previous studies. The study was published on July 3, 2014, in the journal Public Library of Science Neglected Tropical Diseases.


Related Links:

Leiden University Medical Center
PerkinElmer
QIAGEN



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.